ArticleCell2021
Of variants and vaccines.
Article in Cell, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- On modes of disease transmission and the hidden shape of pandemics: A review ofVirus evolution · 2024Article
- Repurposing Niclosamide as a Novel Anti-SARS-CoV-2 Drug by Restricting Entry Protein CD147.Biomedicines · 2023Article
- Repurposing niclosamide as a novel anti-SARS-Cov-2 drug by restricting entry protein CD147.Research square · 2023Article
- SARS-CoV2 mutations and impact on mortality: observational study in a sub-saharan Africa hospital.Virology journal · 2023Observational
- Accelerated SARS-CoV-2 intrahost evolution leading to distinct genotypes during chronic infection.Cell reports. Medicine · 2023Article
- Towards evolutionary predictions: Current promises and challenges.Evolutionary applications · 2023Review
- Article
- COVID-19 vaccine and menstrual conditions in female: data analysis of the Vaccine Adverse Event Reporting System (VAERS).BMC women's health · 2022Article
- Accelerated SARS-CoV-2 intrahost evolution leading to distinct genotypes during chronic infection.medRxiv : the preprint server for health sciences · 2022Article
- COVID-19: Omicron - the latest, the least virulent, but probably not the last variant of concern of SARS-CoV-2.Microbial biotechnology · 2022Review
- Molecular characteristics, immune evasion, and impact of SARS-CoV-2 variants.Signal transduction and targeted therapy · 2022Review
- Modeling suggests that multiple immunizations or infections will reveal the benefits of updating SARS-CoV-2 vaccines.bioRxiv : the preprint server for biology · 2022Article
- Rapid emergence of SARS-CoV-2 Omicron variant is associated with an infection advantage over Delta in vaccinated persons.Med (New York, N.Y.) · 2022Article
- Vaccine models predict rules for updating vaccines against evolving pathogens such as SARS-CoV-2 and influenza in the context of pre-existing immunity.Frontiers in immunology · 2022Article
- Activity-driven network modeling and control of the spread of two concurrent epidemic strains.Applied network science · 2022Article
Corrections and comments
- Comment on
Authors and funding
2 authors.
Funding
Abstract
In this issue of Cell, Bushman et al. show how more transmissible variants, even if they do not escape immunity, can be strongly selected during the early pandemic. This explains the dynamics of past SARS-CoV-2 variants, but as immunity increases, it is difficult to predict what will emerge next.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.